Improving inpatient GHB detoxification with baclofe
Phase 1
- Conditions
- GHB use disorderTherapeutic area: Psychiatry and Psychology [F] - Behavior and Behavior Mechanisms [F01]
- Registration Number
- CTIS2023-506167-34-00
- Lead Sponsor
- Stichting Radboud University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Diagnosed with GUD according to the DSM-V-TR criteria of substance use disorder, Indication for intramural GHB detoxification, GHB use >50ml/day, >18 years old
Exclusion Criteria
Patients who has acute psychiatric co-morbidity that require immediate medical attention and interferes with the execution of the study, such as mania, delirium and psychosis, Physical contra-indications for baclofen, Body weight <55kg, Insufficient understanding of the Dutch language, GHB use >120ml/day, Comorbid benzodiazepine use >30mg diazepam equivalent per day, Use of antihypertensive drugs, Use of tricyclic antidepressant drugs
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method